AstraZeneca Secures EU Approval for Imfinzi as First Perioperative Immunotherapy in Early Gastric Cancer
AstraZeneca announced that its immunotherapy drug Imfinzi has been approved in the European Union for treating early-stage gastric and gastroesophageal cancers. The approval allows Imfinzi to be used alongside standard chemotherapy as a perioperative treatment, marking the first immunotherapy regimen of its kind in this setting. The decision is based on strong Phase III trial results showing improved survival outcomes compared to chemotherapy alone. 
AstraZeneca Secures EU Approval for Imfinzi as First Perioperative Immunotherapy in Early Gastric Cancer